Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

7 U.S.-Based Researchers Share $1.3M Eyesight Prize

September 11, 2014 10:37 am | News | Comments

Seven U.S.-based researchers are sharing a prize of 1 million euro ($1.3 million) from a Portuguese foundation for their work developing treatment for angiogenic diseases of the retina, the leading cause of blindness in the developed world. Read more...

TOPICS:

FDA Approves Weight-Loss Drug Contrave

September 11, 2014 9:57 am | News | Comments

U.S. regulators are greenlighting a new weight-loss drug called Contrave, the third in a string of approvals for anti-obesity treatments. The drug was developed by Orexigen Therapeutics Inc., based in La Jolla, California. Read more...      

TOPICS:

Gates Foundation to Spend $50M on Ebola Response

September 11, 2014 8:30 am | by Donna Gordon Blankinship | News | Comments

The Bill & Melinda Gates Foundation announced that it will spend $50 million- on top of $10 million already committed- to support emergency response to the Ebola outbreak in West Africa. Read more...             

TOPICS:
Advertisement

Method May Enable Portable Detection of ‘Bath Salts’

September 10, 2014 2:30 pm | News | Comments

Despite being outlawed in 2012 in the United States, the synthetic drugs known as “bath salts” are still readily available in some retail shops. To help law enforcement, scientists are developing a novel method that could be the basis for the first portable, on-site testing device for identifying the drugs. Read more...

TOPICS:

Mylan to Acquire Arixtra Rights for $225M

September 10, 2014 2:24 pm | News | Comments

Mylan Inc. announced that its subsidiary Mylan Ireland Ltd. has entered into an agreement to acquire the U.S. commercialization, marketing and intellectual property rights relating to Arixtra Injection, and the authorized generic, from Aspen Global Inc. Read more…

TOPICS:

MabVax Therapeutics, MSK Partner to Develop Anti-Cancer Therapies

September 10, 2014 2:17 pm | News | Comments

MabVax Therapeutics Holdings Inc. announced it has entered into agreements with Memorial Sloan Kettering Cancer Center and Juno Therapeutics for the development of novel therapeutic products using antibody targeting sequences. Read more...

TOPICS:

EMD Serono, Accelerated Cure Project Launch MS Research Program

September 10, 2014 2:09 pm | News | Comments

EMD Serono, Inc. and the Accelerated Cure Project for Multiple Sclerosis announced a lead founding sponsor agreement to help launch the Optimizing Treatment—Understanding Progression (OPT-UP) study. Read more...            

TOPICS:

Blocking One Receptor on Cells Could Halt RA

September 10, 2014 2:00 pm | News | Comments

Researchers have shown for the first time how the activation of a receptor provokes the inflammation and bone degradation of rheumatoid arthritis. Read more...                          

TOPICS:
Advertisement

Drug Safety Report Details 49,000 Undisclosed Side Effect Reports

September 10, 2014 1:45 pm | News | Comments

Healthcare informatics company AdverseEvents Inc. released a special drug safety report that includes an analysis of 48,971 unreleased FAERS reports. Read more...                         

TOPICS:

Antibiotics Do Not Shorten TB Treatment, Trial Finds

September 10, 2014 10:45 am | News | Comments

The results of a Phase 3 clinical trial, called REMoxTB, has found that replacing one of the drugs with the antibiotic moxifloxacin in the standard six-month treatment regimen did not allow the treatment time for TB patients to be shortened to four months. Read more...

TOPICS:

Nutrient Combo May be 'Super Pill' to Treat Depression

September 10, 2014 10:41 am | News | Comments

A new study will help people suffering from clinical depression by offering them new combination of nutrient-based medications to enhance mood. Read more...                           

TOPICS:

FDA Committee Votes Against Actavis Hypertension Drug

September 10, 2014 10:31 am | News | Comments

Actavis confirmed that the FDA Cardiovascular and Renal Drugs Advisory Committee has voted to recommend against approval of Actavis' NDA for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension. Read more...   

TOPICS:

Sleep, Anxiety Meds May Increase Alzheimer's Risk

September 10, 2014 10:23 am | News | Comments

Taking benzodiazepines (widely prescribed drugs to treat anxiety and insomnia) is associated with an increased risk of developing Alzheimer's disease, particularly for long-term users, suggests a new study. Read more...         

TOPICS:

EC Grants Marketing Authorization for Lilly-BI Insulin

September 10, 2014 9:28 am | News | Comments

The European Commission (EC) granted marketing authorization for Eli Lilly and Company and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged two years and above. Read more...    

TOPICS:

Auxilium to Cut 30% of Workforce

September 10, 2014 9:00 am | News | Comments

Auxilium Pharmaceuticals said Tuesday it is cutting 30 percent of its workforce, about 190 jobs, as part of a restructuring of its operations that will save it at least $75 million a year. The moves come as the company struggles with sales of its testosterone replacement gel Testim. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading